STALLERGENES : - 2008: sales up 16%, excellent performance, guidance exceeded

PR Newswire/Les Echos/

STALLERGENES

PRESS RELEASE

2008:SALES UP 16% EXCELLENT PERFORMANCE-GUIDANCE EXCEEDED

Antony,France:15 January 2009-6pm.

EUR millions	          2007         07/06    2008  08/07     
                EUR millions %sales  %change EURmillions %sales   %change 

Southern Europe(1)    32.0    75       14       36.4	73	14
Other EU Countries(2)  9.7    22       17	11.3	23	17
Other markets	       1.4     3       10	 2.0	4	45
SLIT	              34.6    80       21	40.4	81	17
SCIT	               7.1    17        4	 7.5	15	6
Other products	       1.4     3      (25)       1.8	4	32
Total Q4 sales	      43.1   100       15	49.7	100	15
Southern Europe(1)   109.2    74       17      124.9	73	14
Other EU countries(2) 32.5    22       16       38.5	23	18
Other markets	       5.4     4       11        7.5	4	38
SLIT	             116.5    79       21      137.9	81	18
SCIT	              24.9    17        3       26.3	15	6
Other products	       5.7     4       (7)       6.7	4	16
Cumulative 	     147.1   100       16      170.9	100	16
12-month sales

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included


Sales growth and financial position, 2009 outlook

4th quarter sales continued to register strong growth in all markets (up 15%,
after 15% in 2007). The performance of non-EU markets in particular was
remarkable during the quarter, as throughout the whole year. The sub-lingual
route remained the main driver of this growth with an 18% increase over the
financial year.

Overall, 2008 sales totalled EUR 170.9 million, an increase of 16%, in line 
with the strong growth consistently achieved since 2003 (average 15% annual 
growth).

Full-year results will be markedly improved compared to 2007, which will enable
the Group to finance its development plans while maintaining a positive free
cash flow for the fourth consecutive year.

As regards 2009, the Group remains prudent and currently provides guidance of
sales growth between 8 and 10%. 2009 will also feature a number of significant
clinical test results as part of the Oralair programme.

Significant 4th quarter transactions and events

Oralair(r) Grasses quarterly sales in Germany were in line with expectations.
The marketing authorization for the use Oralair(r) Grasses on children, which
should be delivered very soon by the German agency, will set the European mutual
recognition procedure of the product in motion.

On October 27, 2008, Stallergenes obtained authorization (IND) from the FDA for
the use of Oralair(r) Grasses in clinical trials in adults. This study is
proceeding satisfactorily.

In order to exert better control over its operations in Switzerland and Austria,
Stallergenes has launched a procedure aiming at having subsidiaries distribute
its products in these two countries from the start of 2009. At the end of this
procedure, Stallergenes will have a subsidiary in Austria and its current
distributor in Switzerland, TRIMEDAL, will join the Stallergenes Group.

Corporate governance

At today's meeting, the Board of Directors took note of the AFEP/MEDEF
recommendations of October 6, 2008 on the remuneration of directors of listed
companies. The Board considers that these recommendations are consistent with
the Company's corporate governance policy and gave the Remuneration Committee
the responsibility to carry out a detailed review of the rules governing their
implementation within the Group.

Consequently, the Board of Directors confirms in principle that in application
of the Law of 3 July 2008, the AFEP/MEDEF code, as amended, will be the
benchmark the Group will refer to in the preparation of the Chairman of the
Board's report on corporate governance, which will explain and specify the 
rules implemented by the Group.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to
desensitization therapies for the prevention and treatment of allergy-related
respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer
and leader in sublingual desensitization treatments, Stallergenes devotes 20% 
of its sales in gross resources to Research and Development and is actively
involved in the development of a new therapeutic class: sublingual
desensitization tablets.
In 2008, Stallergenes had sales of EUR 170.9 million and provided
desensitization treatments to more than 500,000 patients.

Euronext Paris (Compartment B) 
SBF 120.
ISIN Code: FR0000065674
Reuters Code: GEN.PA
Bloomberg Code: GEN.FP

Additional financial information is available at http://www.stallergenes.com 


Contacts

Albert Saporta - Chairman and CEO
Tel: [phone]
Christian Thiry - Chief Executive Officer
Tel: [phone] - e-mail:[e-mail]

Stallergenes Press Relations
Lise Lemonnier - Communication Manager
Tel: + 33 1 55 59 20 96 - e-mail:[e-mail]

Investor and Analyst Relations
Pavie Finance
Lucile de Fraguier - Tel: + 33 1 42 15 04 39 - e-mail:[e-mail]
                      
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.